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Discovery of chemical start points 
using a variety of methods, 
including;
Phenotypic (whole cell) screening,
Screening against molecular 
targets,
Modification of existing 
compounds.
Multi-parametric optimisation for potency, 
selectivity, physicochemical and pharmacokinetic 
properties and non-clinical safety properties.
Good manufacturing process 
(GMP) scale up and good 
regulatory practice (GRP) 
toxicology.
Phase 1: Pharmacokinetics and tolerability 
in healthy human volunteers.
Phase 2: Proof of concept in patients.
Phase 3: Large efficacy and safety study 
in patients.
Phase 4: Post market 
surveillance.
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